Arslan F - Search Results

1

The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction.

van Hout GP, Bosch L, Ellenbroek GH, de Haan JJ, van Solinge WW, Cooper MA, Arslan F, de Jager SC, Robertson AA, Pasterkamp G, Hoefer IE. van Hout GP, et al. Among authors: arslan f. Eur Heart J. 2017 Mar 14;38(11):828-836. doi: 10.1093/eurheartj/ehw247. Eur Heart J. 2017. PMID: 27432019

2

Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets.

Arslan F, de Kleijn DP, Timmers L, Doevendans PA, Pasterkamp G. Arslan F, et al. Curr Pharm Des. 2008;14(12):1205-16. doi: 10.2174/138161208784246090. Curr Pharm Des. 2008. PMID: 18473868 Review.

3

Unraveling pleiotropic effects of statins: bit by bit, a slow case with perspective.

Arslan F, Pasterkamp G, de Kleijn DP. Arslan F, et al. Circ Res. 2008 Aug 15;103(4):334-6. doi: 10.1161/CIRCRESAHA.108.182220. Circ Res. 2008. PMID: 18703784 No abstract available.

4

Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium.

Timmers L, Lim SK, Arslan F, Armstrong JS, Hoefer IE, Doevendans PA, Piek JJ, El Oakley RM, Choo A, Lee CN, Pasterkamp G, de Kleijn DP. Timmers L, et al. Among authors: arslan f. Stem Cell Res. 2007 Nov;1(2):129-37. doi: 10.1016/j.scr.2008.02.002. Epub 2008 Mar 8. Stem Cell Res. 2007. PMID: 19383393 Free article.

5

Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody.

Arslan F, Smeets MB, O'Neill LA, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA, Pasterkamp G, de Kleijn DP. Arslan F, et al. Circulation. 2010 Jan 5;121(1):80-90. doi: 10.1161/CIRCULATIONAHA.109.880187. Epub 2009 Dec 21. Circulation. 2010. PMID: 20026776

6

Endogenous inflammatory molecules engage Toll-like receptors in cardiovascular disease.

Ionita MG, Arslan F, de Kleijn DP, Pasterkamp G. Ionita MG, et al. Among authors: arslan f. J Innate Immun. 2010;2(4):307-15. doi: 10.1159/000314270. Epub 2010 Apr 30. J Innate Immun. 2010. PMID: 20431283 Free article. Review.

7

Lack of fibronectin-EDA promotes survival and prevents adverse remodeling and heart function deterioration after myocardial infarction.

Arslan F, Smeets MB, Riem Vis PW, Karper JC, Quax PH, Bongartz LG, Peters JH, Hoefer IE, Doevendans PA, Pasterkamp G, de Kleijn DP. Arslan F, et al. Circ Res. 2011 Mar 4;108(5):582-92. doi: 10.1161/CIRCRESAHA.110.224428. Epub 2011 Feb 24. Circ Res. 2011. PMID: 21350212

8

Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction.

Timmers L, Lim SK, Hoefer IE, Arslan F, Lai RC, van Oorschot AA, Goumans MJ, Strijder C, Sze SK, Choo A, Piek JJ, Doevendans PA, Pasterkamp G, de Kleijn DP. Timmers L, et al. Among authors: arslan f. Stem Cell Res. 2011 May;6(3):206-14. doi: 10.1016/j.scr.2011.01.001. Epub 2011 Jan 28. Stem Cell Res. 2011. PMID: 21419744 Free article.

9

Innate immune signaling in cardiac ischemia.

Arslan F, de Kleijn DP, Pasterkamp G. Arslan F, et al. Nat Rev Cardiol. 2011 May;8(5):292-300. doi: 10.1038/nrcardio.2011.38. Epub 2011 Mar 29. Nat Rev Cardiol. 2011. PMID: 21448140 Review.

10

The innate immune response in reperfused myocardium.

Timmers L, Pasterkamp G, de Hoog VC, Arslan F, Appelman Y, de Kleijn DP. Timmers L, et al. Among authors: arslan f. Cardiovasc Res. 2012 May 1;94(2):276-83. doi: 10.1093/cvr/cvs018. Epub 2012 Jan 20. Cardiovasc Res. 2012. PMID: 22266751 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

331 results

Search Page

Filters